Boehringer Ingelheim 自 Immunitas Therapeutics 取得臨床前抗體計畫授權，以推進慢性發炎性疾病治療

• 這項首創的單株抗體計畫旨在選擇性地 targeting 致病細胞，有望比現行療法提供更深入且持久的疾病控制。
• 該協議強化了Boehringer Ingelheim不斷成長的免疫學藥物組合，並建立在其近期其他研究合作聲明之上。

(SeaPRwire) –   Ingelheim, Germany 和 Waltham, Massachusetts, U.S., May X, 2026 – Boehringer Ingelheim與Immunitas Therapeutics today announced a global licensing agreement for a preclinical antibody program being developed for chronic inflammatory and autoimmune diseases. The program is designed to selectively target cells that play a central role in driving chronic inflammation, with the goal of achieving sustained disease control for patients who do not respond adequately to current therapies.

慢性發炎性和自身免疫性疾病影響全球數百萬患者，並可能嚴重影響生活品質。雖然現行療法已使部分患者獲益，但許多人隨著時間推移會經歷療效有限或逐漸減退的問題。需要新的治療方法來針對炎症的根本原因，以實現更長期的疾病控制。

與僅阻斷單一發炎信號的療法不同，Immunitas授權的抗體計畫旨在 targeting 位於發炎部位的致病細胞。透過 targeting 這群致病細胞，此方法有潛力在多種發炎性疾病中提供更深層且效果更持久的好處。

「這項協議擴大了我們針對 autoimmune 和發炎性疾病的 growing pipeline，並體現了我們致力於開發能為患者帶來實質長期效益療法的承諾，」Boehringer Ingelheim免疫學與呼吸道疾病全球負責人暨美國創新事業部 site head Carine Boustany 表示。「透過將這項差異化的 preclinical 計畫加入我們的既有產品組合，我們希望能彌補現行治療選項不足之處。」

「此計畫源自 Immunitas 對人類生物學的深入探索，我們已在 preclinical 階段 extensively explored 這些 insights。 partnering with Boehringer Ingelheim 讓我們能借助其在全球免疫學與藥物研發方面的深厚 expertise，推動這項新型療法進入臨床開發階段，」Immunitas Therapeutics 總裁兼執行長 Amanda Wagner 表示。「我們相信這項合作有潛力將 our science 轉化為 living with chronic inflammatory diseases 的患者提供更好的解決方案。」

The agreement further strengthens Boehringer Ingelheim’s growing pipeline in autoimmune and inflammatory diseases and builds on a series of recent partnerships in this therapeutic area. Boehringer Ingelheim will leverage its global research, development, manufacturing and commercialization capabilities to advance the program toward clinical development and, ultimately, to patients worldwide.

Under the terms of the agreement, Boehringer Ingelheim will obtain worldwide rights to develop, manufacture and commercialize the antibody program. Immunitas Therapeutics will receive an upfront payment and is eligible to receive near-term and future development, regulatory, and commercial milestone payments totaling up to €407.5 million, in addition to tiered royalties on future sales. Further details of the agreement are not being disclosed.

關於 Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.

關於 Immunitas Therapeutics

Immunitas is a clinical stage precision immunotherapy company dedicated to discovering and developing novel treatments for patients with cancer and autoimmune disease. The company was founded in 2019 by Longwood Fund with leading scientists from Dana-Farber Cancer Institute, Massachusetts General Hospital, Broad Institute, and Massachusetts Institute of Technology.  Immunitas is supported by a strong syndicate of investors including Agent Capital, Alexandria Venture Investments, Evotec, Leaps by Bayer, Longwood Fund, M Ventures, Medical Excellence Capital, and Novartis Venture Fund. To learn more, visit www.immunitastx.com.